COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Actigraphy in Pediatric Pulmonary Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02909608
Recruitment Status : Recruiting
First Posted : September 21, 2016
Last Update Posted : July 10, 2019
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
Physical activity is an important factor in understanding how diseases can affect a child. Decreases in physical activity are sometimes the first thing that happens before a child is diagnosed with a disease. When a child sees their doctor, that visit reflects a single point in time. It does not capture how a child feels during the days in between visits to their doctor. This study plans to use special monitors called actigraphs to collect information about physical activity in children with a type of disease called pulmonary hypertension. This study will measure how active these children are and compare their activity to clinical information and to actigraphy measurements in children without pulmonary hypertension.

Condition or disease Intervention/treatment
Pediatric Pulmonary Hypertension Other: No interventions / observations only

Detailed Description:

Pediatric pulmonary arterial hypertension (PAH) (roughly 1-5 cases per 1 million children) is a severe disorder with high mortality and morbidity, but limited treatment options. Pediatric PAH is defined the same as that in adults, which is the presence of abnormally high pulmonary artery pressure. In comparison with adults, pediatric PAH is likely a more severe disorder with higher mortality and morbidity without treatment. Except for INOmax for persistent pulmonary hypertension of the newborn, no drug is currently approved in the US to treat pediatric PAH patients 1-17 years of age. Drug development to treat pediatric PAH is an unmet public health need for children and a priority for the Food and Drug Administration (FDA). However, studies that address the safety and efficacy of PAH therapies are rare, in part due to the lack of suitable clinical endpoints and quantitative and qualitative measures of disease severity.

A major limitation towards enhancing outcomes of children with PAH is the lack of pediatric efficacy endpoints or surrogate measures that are capable of reproducibly and reliably reflecting changes in pulmonary arterial pressure in response to a therapeutic intervention that is being assessed in a pediatric clinical trial. Children are often too young and developmentally unable to perform standard cardiopulmonary exercise testing and the use of several metrics are not as accurate for reflecting clinical status in children as in adults, such as 6 minute walking distance. Additionally, the use of cardiac catheterization to directly measure pulmonary vascular resistance is invasive, requires anesthesia, and has additional risks for complications.

Therefore, to address this critical and unmet medical need in children with PAH, we propose to begin develop a novel, developmentally-appropriate non-invasive endpoint in children through the use of actigraphy. Actigraphy is a mobile device that directly, reproducibly and non-invasively measures physical activity, which can be readily assessed in the ambulatory setting, and may provide a novel, simple and inexpensive approach. Impaired exercise tolerance is a prominent feature of PAH and contributes significantly to reduced quality of life. Assessing exercise capacity is an integral part of the clinical evaluation of PAH in adults and the use of the 6 minute walk distance (6MWD) is the most common primary endpoint in adult PAH clinical trials. Importantly, the 6MWD test and other existing exercise performance tests that are readily applied in adult studies are not reliable and applicable for young children and infants. We propose that actigraphy may provide a novel endpoint for assessing drug efficacy in children if proven to be strongly predictive and reflect clinical course and outcomes of children with PAH. If successful, this early study has great potential for having a significant regulatory impact that will advance the public health mission, as actigraphy could possibly become an endpoint that would be accepted in pediatrics as a regulatory standard for PAH clinical trials.

The purpose of the current study is to describe the use of actigraphy in children with PAH and to determine if correlations exist between actigraphy data and clinical data in children with PAH.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Investigation of Actigraphy, an Exercise Measurement Device, as a Novel, Well-defined, Reliable, Feasible, Easy to Use, and Non-Invasive Study Endpoint to Facilitate Pediatric Pulmonary Arterial Hypertension Trials and Drug Development
Actual Study Start Date : October 7, 2016
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020

Group/Cohort Intervention/treatment
Controls Other: No interventions / observations only
This is an observational study only
Other Name: There are no interventions as part of this study

Children With Pulmonary Hypertension Other: No interventions / observations only
This is an observational study only
Other Name: There are no interventions as part of this study

Primary Outcome Measures :
  1. Investigate and define the utility of the measurement properties of actigraphy in children with PAH [ Time Frame: At Baseline and again at Week 26 ]
    Children will wear both actigraphy devices for 2 weeks at 2 different time points. The first time point is at Baseline when the child enters the study. The second time point is at Week 26, which is 26 weeks after the Baseline timepoint.

Secondary Outcome Measures :
  1. Use statistical analysis to determine correlations of actigraphy with disease severity, progression, clinical worsening, and survival, based on data from this prospective clinical study. [ Time Frame: For 18 months ]
    Children with PH will have information collected from their medical charts that will be compared to their actigraphy data

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
We will include children with pulmonary hypertension and children without pulmonary hypertension into this study. All enrolled children must be between the ages of 8-14 years at the time of enrollment.

Inclusion Criteria for children with PAH:

  1. Ages 8-14 years at the time of consent
  2. Current diagnosis of pulmonary hypertension in WHO Diagnostic Group 1 as per established clinical criteria

Inclusion Criteria for Control children:

  1. Ages 8-14 years at the time of consent
  2. Absence of significant cardiopulmonary disease as per medical history

Exclusion criteria for children with PAH:

  1. Current disease severity of Panama functional class IIIb or IV
  2. Any bone, neuromuscular, or other pathology that may limit activity
  3. Use of any medications known to limit activity
  4. Active infection, or has any of the following:

    • cardiovascular,
    • liver,
    • renal,
    • hematologic,
    • gastrointestinal,
    • immunologic,
    • endocrine,
    • metabolic, or
    • central nervous system

    disease or condition that, in the opinion of the Investigator, may adversely affect the safety of the subject or interfere with the interpretation of study assessments.

  5. Actively listed for transplantation
  6. Subject and/or legal guardian has/have

    • an unstable psychiatric condition or
    • is/are mentally incapable of understanding the objectives, nature, or consequences of the trial, or
    • has any condition in which the Investigator's opinion would constitute an unacceptable risk to the subject's safety.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02909608

Layout table for location contacts
Contact: Suzette Bossart, MS 720-777-8669
Contact: Amy Taylor, PhD 720-777-4981

Layout table for location information
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Nikki Bloch    720-777-5809   
Principal Investigator: Sumeet Garg, MD         
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Ivy Dunbar         
Sponsors and Collaborators
University of Colorado, Denver
Layout table for investigator information
Principal Investigator: Dunbar Ivy, MD University of Colorado, Denver
Layout table for additonal information
Responsible Party: University of Colorado, Denver Identifier: NCT02909608    
Other Study ID Numbers: 16-1422
First Posted: September 21, 2016    Key Record Dates
Last Update Posted: July 10, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases